PC20-01b

Main Content

Impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastomas.

Study #: PC20-01b

Study Status: Published

Presentation(s)

2022, Tandem (Poster)

No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma.

Citation

Knight TE, Ahn KW, Hebert KM, Atshan R, Wall DA, Chiengthong K, Lund TC, Prestidge T, Rangarajan HG, Dvorak CC, Auletta JJ, Kent M, Hashem H, Talano JA, Rotz SJ, Fraint E, Myers KC, Leung W, Sharma A, Bhatt NS, Driscoll TA, Yu LC, Schultz KR, Qayed M, Broglie L, Eapen M, Yanik GA.

Bone Marrow Transplantation. 2023, Dec 01: 58(12): 58(12):1390-1393. doi: 10.1038/s41409-023-02092-3. Epub 2023, Sep 04. PMCID:PMC11221560.

PubMed

PMID: 37666957

Abstract